
Windtree Therapeutics WINT
Windtree Therapeutics ROCE Ratio | WINT
Annual ROCE Ratio Windtree Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -261.49 | -607.4 | -412.83 | -184.52 | -28.4 | -24.01 | -19.78 | 198.79 | 1030.23 | -154.89 | -109.04 | -57.51 | -207.8 | -1114.09 | -423.63 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1030.23 | -1114.09 | -158.43 |
Quarterly ROCE Ratio Windtree Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.51 | -585.52 | -503.6 | -463.86 | -526.52 | -477.22 | -209.09 | -180.52 | -207.21 | -235.91 | -201.67 | -142.05 | -158.28 | -211.5 | -130.07 | -106.07 | -118.59 | -113.78 | -43.5 | -33.58 | -39.66 | -36.73 | -33.97 | -33.22 | -34.26 | -29.76 | -25.55 | -23.78 | -2.03 | 23.1 | 53.23 | 94.26 | 101.73 | 108.51 | 117.5 | 131.93 | -8.48 | -137.45 | -298.37 | -481.9 | -422.05 | -373.69 | -304.42 | -225.31 | -184.39 | -149.08 | -110.57 | -76.08 | -128.92 | -167.07 | -198.53 | -214.24 | -610.86 | -1042.36 | -1497.16 | -1939.24 | -488.13 | -504.75 | -479.35 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 131.93 | -1939.24 | -244.17 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
-61.88 | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
-431.71 | - | 7.29 % | $ 127 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-141.18 | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
-159.95 | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
-128.38 | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
289.47 | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-175.6 | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-29.63 | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
74.33 | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-41.99 | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-71.67 | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-92.11 | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-17.17 | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
9.07 | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-5.84 | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-68.09 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-25.89 | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-134.09 | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-46.52 | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-1610.96 | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-106.49 | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-60.71 | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-69.47 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-235.23 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-36.31 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-53.23 | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
11.01 | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-141.76 | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-96.98 | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-106.57 | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
458.12 | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
1322.0 | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
166.56 | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
102.23 | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-242.78 | - | 31.87 % | $ 1.61 M |